Clinical trial
Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited…
NCT00193375 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193375 |
|---|---|
| Title | Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer |
| Official title | Phase II Trial of Concurrent Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab (Avastin) in the Treatment of Patients With Limited Stage Small Cell Lung Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Genentech, Inc. Industry Pharmacia and Upjohn |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug, Radiation |
| Interventions | Irinotecan, Carboplatin, Bevacizumab, Radiation |
| Enrollment | 60 |
| Start date | Aug 1, 2003 |
| Primary completion | Apr 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Sep 19, 2005 |
| Last update posted | Aug 10, 2016 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: